Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein
SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectio...
Saved in:
| Published in | Virology journal Vol. 18; no. 1; p. 16 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
12.01.2021
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature.
To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA).
The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA.
In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2. |
|---|---|
| AbstractList | SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature.BACKGROUNDSARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature.To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA).METHODSTo circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA).The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA.RESULTSThe CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA.In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2.CONCLUSIONSIn conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2. SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature. To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA). The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA. In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2. Background SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature. Methods To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA). Results The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA. Conclusions In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2. Keywords: Pseudotyped virus, VSV, SARS-CoV-2, Neutralization assay, Serum, Whole blood Background SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature. Methods To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA). Results The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA. Conclusions In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2. SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature. To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA). The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA. In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2. Abstract Background SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature. Methods To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA). Results The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA. Conclusions In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2. |
| ArticleNumber | 16 |
| Audience | Academic |
| Author | Tan, Long Kishi, Hiroyuki Saijo, Masayuki Suzuki, Tadaki Fukui, Yasutaka Yoshida, Yoshihiro Miyajima, Yuki Ozawa, Tatsuhiko Yamamoto, Yoshihiro Sano, Kaori Ueno, Akitoshi Sakamaki, Ippei Kawasuji, Hitoshi Fukushi, Shuetsu Tani, Hideki Kimura, Miyuki Morinaga, Yoshitomo |
| Author_xml | – sequence: 1 givenname: Hideki orcidid: 0000-0002-6309-277X surname: Tani fullname: Tani, Hideki – sequence: 2 givenname: Miyuki surname: Kimura fullname: Kimura, Miyuki – sequence: 3 givenname: Long surname: Tan fullname: Tan, Long – sequence: 4 givenname: Yoshihiro surname: Yoshida fullname: Yoshida, Yoshihiro – sequence: 5 givenname: Tatsuhiko surname: Ozawa fullname: Ozawa, Tatsuhiko – sequence: 6 givenname: Hiroyuki surname: Kishi fullname: Kishi, Hiroyuki – sequence: 7 givenname: Shuetsu surname: Fukushi fullname: Fukushi, Shuetsu – sequence: 8 givenname: Masayuki surname: Saijo fullname: Saijo, Masayuki – sequence: 9 givenname: Kaori surname: Sano fullname: Sano, Kaori – sequence: 10 givenname: Tadaki surname: Suzuki fullname: Suzuki, Tadaki – sequence: 11 givenname: Hitoshi surname: Kawasuji fullname: Kawasuji, Hitoshi – sequence: 12 givenname: Akitoshi surname: Ueno fullname: Ueno, Akitoshi – sequence: 13 givenname: Yuki surname: Miyajima fullname: Miyajima, Yuki – sequence: 14 givenname: Yasutaka surname: Fukui fullname: Fukui, Yasutaka – sequence: 15 givenname: Ippei surname: Sakamaki fullname: Sakamaki, Ippei – sequence: 16 givenname: Yoshihiro surname: Yamamoto fullname: Yamamoto, Yoshihiro – sequence: 17 givenname: Yoshitomo surname: Morinaga fullname: Morinaga, Yoshitomo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33435994$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkkuP0zAURiM0iHnAH2CBIrGBRYb4ldgbpKoaoNJISDOA2Fmuc11cUrtjO-Xx63HaYWhHCJSFo-tzT5zr77Q4ct5BUTxF9TlCvHkVERacVTVGVY2oqKv2QXGCWkoqivHno7334-I0xmVdE9y04lFxTAglTAh6Uny72Kh-UMl6V3pTXk-urqup_1Th0sGQgurtT-sWpXLJzn1nIZZD3BbKDUSrh16FMia_yoZkY7mxYYjl2scIccvtCePafoVyHXwC6x4XD43qIzy5Xc-Kj28uPkzfVZfv386mk8tKN6JJFRBRC6AUkRZQZzrWcWiIxsJoEMwYxjTimBCgyiCNma6JbglDDUdGGUHIWTHbeTuvlnId7EqFH9IrK7cFHxZShWR1D1I0Le_moBoK3fhBPjcd0YpqPscddDq7Xu9c62G-ygVw44AOpIc7zn6RC7-RLa_zfdEseHErCP5mgJjkykYNfa8c-CFKzPKFsSaT_0dp21LRNGi0Pr-HLv0QXJ7qSHFOCKfsD7VQ-V-tMz4fUY9SOWkYyblAGGXq_C9UfjpYWZ3jZ2yuHzS8PGjITILvaaGGGOXs-uqQfbY_v7vB_U5jBvAO0CEnKIC5Q1Atx8jLXeRljrzcRl62uYnfa9I2bQOdj277f7X-AuZABD4 |
| CitedBy_id | crossref_primary_10_3390_md22110486 crossref_primary_10_1007_s11596_021_2470_7 crossref_primary_10_1016_j_jiac_2022_05_009 crossref_primary_10_1002_jmv_28543 crossref_primary_10_7883_yoken_JJID_2023_100 crossref_primary_10_1039_D2SC06665C crossref_primary_10_1126_scitranslmed_adp9927 crossref_primary_10_1128_spectrum_05131_22 crossref_primary_10_1016_j_heliyon_2023_e17477 crossref_primary_10_1016_j_vaccine_2022_02_044 crossref_primary_10_1016_j_vaccine_2023_02_068 crossref_primary_10_1016_j_vaccine_2024_05_077 crossref_primary_10_1139_bcb_2021_0342 crossref_primary_10_1016_j_medj_2022_02_006 crossref_primary_10_1080_19420862_2022_2072455 crossref_primary_10_1016_j_jgr_2022_07_003 crossref_primary_10_1016_j_xcrm_2022_100631 crossref_primary_10_1016_j_immuni_2021_08_025 crossref_primary_10_1017_S0022029924000657 crossref_primary_10_1038_s41598_023_35915_w crossref_primary_10_1038_s41467_023_39890_8 crossref_primary_10_1128_Spectrum_00561_21 crossref_primary_10_3390_microorganisms11020431 crossref_primary_10_1016_j_bios_2022_114449 crossref_primary_10_1038_s41467_023_37128_1 crossref_primary_10_1016_j_isci_2023_105969 crossref_primary_10_2139_ssrn_3956654 crossref_primary_10_5858_arpa_2022_0041_SA crossref_primary_10_1038_s41598_024_73004_8 crossref_primary_10_1038_s41598_022_15258_8 crossref_primary_10_1126_sciadv_adf0661 crossref_primary_10_1016_j_idairyj_2023_105805 crossref_primary_10_1038_s41598_024_75038_4 crossref_primary_10_1128_Spectrum_00560_21 crossref_primary_10_1038_s41598_023_38757_8 crossref_primary_10_1038_s41598_021_96143_8 crossref_primary_10_1126_sciimmunol_abn8590 crossref_primary_10_1080_22221751_2022_2030198 crossref_primary_10_1021_acs_analchem_3c05144 crossref_primary_10_3389_fimmu_2023_1061255 crossref_primary_10_1128_jvi_01389_24 crossref_primary_10_1093_jb_mvae037 crossref_primary_10_1128_spectrum_03655_23 crossref_primary_10_1016_j_trac_2021_116253 crossref_primary_10_1016_j_jviromet_2021_114221 crossref_primary_10_1155_2022_5714035 crossref_primary_10_3390_v15071504 crossref_primary_10_1016_j_immuni_2021_06_015 crossref_primary_10_1128_mbio_01092_24 crossref_primary_10_3389_fimmu_2024_1377014 |
| Cites_doi | 10.3390/vaccines8030386 10.1128/JVI.00512-14 10.1128/JVI.00110-16 10.1128/JVI.01933-08 10.1016/j.chom.2020.06.021 10.3390/v12040372 10.1016/j.jviromet.2010.08.006 10.1016/j.jinf.2020.04.011 10.1038/s41587-020-0631-z 10.1016/S0140-6736(20)30183-5 10.1128/JCM.40.5.1587-1591.2002 10.1038/s41591-020-0913-5 10.1038/s41598-017-10865-2 10.1080/22221751.2020.1743767 10.1089/hgtb.2017.084 10.7883/yoken.JJID.2020.061 10.1002/rmv.1963 10.1099/vir.0.80955-0 10.3390/v12050513 10.1128/JVI.02499-09 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
| Copyright_xml | – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7U9 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM DOA |
| DOI | 10.1186/s12985-021-01490-7 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database MEDLINE AGRICOLA |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1743-422X |
| EndPage | 16 |
| ExternalDocumentID | oai_doaj_org_article_9678dbea64ed41378bfd3ca4c8b2dedc PMC7801864 A653679121 33435994 10_1186_s12985_021_01490_7 |
| Genre | Evaluation Study Journal Article |
| GeographicLocations | Japan United States--US |
| GeographicLocations_xml | – name: Japan – name: United States--US |
| GrantInformation_xml | – fundername: Japan Agency for Medical Research and Development grantid: JP19fk0108110 – fundername: Japan Agency for Medical Research and Development (JP) grantid: JP20he0622035 – fundername: ; grantid: JP19fk0108110 – fundername: ; grantid: JP20he0622035 |
| GroupedDBID | --- 0R~ 123 29Q 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAHBH AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IGS IHR INH INR ISR ITC KQ8 LGEZI LOTEE M1P M48 M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP WOQ WOW XSB -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF IFM NPM PMFND PJZUB PPXIY 7U9 7XB 8FK AZQEC COVID DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 7S9 L.6 5PM PUEGO |
| ID | FETCH-LOGICAL-c696t-e3909e44137e1dfd5d8e63c29fce95ff55c18233e4af1c25c03c7351681faf933 |
| IEDL.DBID | M48 |
| ISSN | 1743-422X |
| IngestDate | Wed Aug 27 01:30:43 EDT 2025 Thu Aug 21 14:09:17 EDT 2025 Thu Jul 10 21:58:54 EDT 2025 Thu Jul 10 22:46:36 EDT 2025 Fri Jul 25 23:44:19 EDT 2025 Mon Aug 11 06:00:10 EDT 2025 Tue Jun 10 20:49:29 EDT 2025 Fri Jun 27 04:19:26 EDT 2025 Thu Jan 02 22:57:22 EST 2025 Thu Apr 24 22:53:33 EDT 2025 Tue Jul 01 01:44:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Whole blood VSV Pseudotyped virus Serum Neutralization assay SARS-CoV-2 |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c696t-e3909e44137e1dfd5d8e63c29fce95ff55c18233e4af1c25c03c7351681faf933 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| ORCID | 0000-0002-6309-277X |
| OpenAccessLink | https://www.proquest.com/docview/2478833845?pq-origsite=%requestingapplication% |
| PMID | 33435994 |
| PQID | 2478833845 |
| PQPubID | 55248 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9678dbea64ed41378bfd3ca4c8b2dedc pubmedcentral_primary_oai_pubmedcentral_nih_gov_7801864 proquest_miscellaneous_2574356643 proquest_miscellaneous_2477496614 proquest_journals_2478833845 gale_infotracmisc_A653679121 gale_infotracacademiconefile_A653679121 gale_incontextgauss_ISR_A653679121 pubmed_primary_33435994 crossref_primary_10_1186_s12985_021_01490_7 crossref_citationtrail_10_1186_s12985_021_01490_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-12 |
| PublicationDateYYYYMMDD | 2021-01-12 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Virology journal |
| PublicationTitleAlternate | Virol J |
| PublicationYear | 2021 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | H Tani (1490_CR16) 2010; 84 Y Jin (1490_CR4) 2020; 12 M Saijo (1490_CR13) 2002; 40 1490_CR17 CW Tan (1490_CR11) 2020; 38 A Musa (1490_CR2) 2020; 21 AV Joglekar (1490_CR6) 2017; 28 J Nie (1490_CR8) 2020; 9 MA Whitt (1490_CR7) 2010; 169 F Amanat (1490_CR18) 2020; 26 SA Almahboub (1490_CR12) 2020; 2020 H Tani (1490_CR20) 2014; 88 C Huang (1490_CR1) 2020; 395 H Tani (1490_CR21) 2016; 90 F Zettl (1490_CR10) 2020; 8 M Sakata (1490_CR19) 2017; 7 Q Li (1490_CR5) 2018; 28 S Fukushi (1490_CR14) 2005; 86 M Kawase (1490_CR15) 2009; 83 JB Case (1490_CR9) 2020; 28 H Tu (1490_CR3) 2020; 81 KHD Crawford (1490_CR22) 2020; 12 |
| References_xml | – volume: 8 start-page: 386 year: 2020 ident: 1490_CR10 publication-title: Vaccines (Basel) doi: 10.3390/vaccines8030386 – volume: 88 start-page: 7317 year: 2014 ident: 1490_CR20 publication-title: J Virol doi: 10.1128/JVI.00512-14 – volume: 90 start-page: 5292 year: 2016 ident: 1490_CR21 publication-title: J Virol doi: 10.1128/JVI.00110-16 – volume: 83 start-page: 712 year: 2009 ident: 1490_CR15 publication-title: J Virol doi: 10.1128/JVI.01933-08 – volume: 28 start-page: e475 issue: 475–485 year: 2020 ident: 1490_CR9 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2020.06.021 – volume: 12 start-page: 372 year: 2020 ident: 1490_CR4 publication-title: Viruses doi: 10.3390/v12040372 – volume: 169 start-page: 365 year: 2010 ident: 1490_CR7 publication-title: J Virol Methods doi: 10.1016/j.jviromet.2010.08.006 – volume: 81 start-page: 1 year: 2020 ident: 1490_CR3 publication-title: J Infect doi: 10.1016/j.jinf.2020.04.011 – volume: 38 start-page: 1073 year: 2020 ident: 1490_CR11 publication-title: Nat Biotechnol doi: 10.1038/s41587-020-0631-z – volume: 395 start-page: 497 year: 2020 ident: 1490_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – volume: 21 start-page: 737 year: 2020 ident: 1490_CR2 publication-title: West J Emerg Med – volume: 40 start-page: 1587 year: 2002 ident: 1490_CR13 publication-title: J Clin Microbiol doi: 10.1128/JCM.40.5.1587-1591.2002 – volume: 26 start-page: 1033 year: 2020 ident: 1490_CR18 publication-title: Nat Med doi: 10.1038/s41591-020-0913-5 – volume: 7 start-page: 11607 year: 2017 ident: 1490_CR19 publication-title: Sci Rep doi: 10.1038/s41598-017-10865-2 – volume: 9 start-page: 680 year: 2020 ident: 1490_CR8 publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2020.1743767 – volume: 28 start-page: 291 year: 2017 ident: 1490_CR6 publication-title: Many Guises Hum Gene Ther Methods doi: 10.1089/hgtb.2017.084 – ident: 1490_CR17 doi: 10.7883/yoken.JJID.2020.061 – volume: 28 start-page: e1963 year: 2018 ident: 1490_CR5 publication-title: Rev Med Virol doi: 10.1002/rmv.1963 – volume: 86 start-page: 2269 year: 2005 ident: 1490_CR14 publication-title: J Gen Virol doi: 10.1099/vir.0.80955-0 – volume: 12 start-page: 513 year: 2020 ident: 1490_CR22 publication-title: Viruses doi: 10.3390/v12050513 – volume: 2020 start-page: 11 year: 2020 ident: 1490_CR12 publication-title: Front Microbiol – volume: 84 start-page: 2798 year: 2010 ident: 1490_CR16 publication-title: J Virol doi: 10.1128/JVI.02499-09 |
| SSID | ssj0032679 |
| Score | 2.4821546 |
| Snippet | SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly... Background SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is... BACKGROUND: SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is... Abstract Background SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV.... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 16 |
| SubjectTerms | Animals Antibodies Antibodies, Neutralizing - blood Antibodies, Neutralizing - immunology Antibodies, Viral - blood Antibodies, Viral - immunology Antigens biosafety blood serum Cell Line Chemiluminescence Cloning Convalescence Coronaviruses COVID-19 COVID-19 - blood COVID-19 - immunology COVID-19 infection COVID-19 Serological Testing - methods Enzyme-linked immunosorbent assay fluorescent antibody technique Genetic aspects Health aspects Hospitalization Humans Immune response Immunofluorescence Infections Inhibitory Concentration 50 luciferase Luminescence Lymphocytes neutralization Neutralization assay neutralization tests Neutralization Tests - methods Observations pathogens Patients Plasmids Proteins Pseudotyped virus SARS-CoV-2 SARS-CoV-2 - genetics SARS-CoV-2 - immunology Sensitivity analysis Serum Severe acute respiratory syndrome coronavirus 2 Spike Glycoprotein, Coronavirus - genetics Spike Glycoprotein, Coronavirus - immunology Spike protein Stomatitis Vesicular stomatitis Indiana virus - genetics Vesiculovirus Viral antibodies Viral infections Viral proteins virology Viruses VSV Whole blood |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJRAXBOUVKMggJA7I6ia2Y_u4VK0KUjl0KerNSvyACJSsmt0i-PXMONnVRkjlwtUeR8l4PPM5Hn9DyBtZcx1iwZlQXDGh68CMMJ6JSroixplSHi8Kn30qTy_Ex0t5uVPqC3PCBnrgQXGHBrypr0NViuDB4SpdR89dJZyuCx-8Q-8LMW-zmRp8MGASZTZXZHR52ENU03gTGbfOwsyYmoShxNb_t0_eCUrThMmdCHRyn9wboSOdD6_8gNwK7T65PRST_LVP7pyNx-QPyc_jLYc37SJdzM8X7Kj7wgrahnX6tfEbIhYFpTZ1h2mEFNPfoYFeh75JmakUQGECs01Pr5urdU-XXTofRrmdB_bL5nugie2haR-Ri5Pjz0enbKywwFxpyhUL3MxMEKjXkPvopdeh5K4w0QUjY5TSwf6D8yCqmLtCuhl3isu81HmsouH8MdlruzY8JRSZ9WRteK2RUi_3phIzHsEPw5AKUExG8o3CrRvpx7EKxg-btiG6tMMkWZgkmybJqoy8245ZDuQbN0q_x3ncSiJxdmoAc7KjOdl_mVNGXqMVWKTGaDH35mu17nv7YXFu56XkYFZ5kWfk7SgUO_gGV41XGUATyKY1kTyYSMLaddPujbHZ0Xf0tsCKBpxrITPyatuNIzEfrg3dOskoYRBb3SAjAR0CWhc8I08G-93qhnPoMgZGq4llT5Q37Wmbb4l9XAGm0aV49j-0_ZzcLYZFyfLigOytrtbhBYC8Vf0yrec_PrJO4A priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELagCMQFQXktFGQQEgdkdeNHHJ_QUrUqSOXQpWhvVuLYJQIly2a3CH49M042bITUazyOEs_rsz3-TMgbVYjMBy6Y1EIzmRWeGWlKJnPleAhTrUs8KHz2OT29kJ8WatEvuLV9WeU2JsZAXTYO18gPOfK8w3xKqvfLnwxvjcLd1f4KjZvkFlKXYUmXXgwTLkAmkWsPQTeTnC-2h2ay9LCFPJfh2WScTEszZXqUmCJ___9ReidNjUsod3LSyX1yrweTdNZp_wG54et9cru7XvL3Prlz1m-cPyS_jgdWb9oEOp-dz9lR85VxWvtNXOz4AzmMwjBXRYOFhRQL4uEBvfJtFWtVKcDECG-rll5Vq01Ll03cMUa5nRe2y-q7p5H_oaofkYuT4y9Hp6y_c4G51KRr5oWZGg8YSWiflKFUZeZT4bgJzhsVglIOZiRCeJmHxHHlpsJpoZI0S0IejBCPyV7d1P4poci1pwojigxJ9pLS5HIqAkRm6JIDrpmQZDvg1vWE5Hgvxg8bJyZZajslWVCSjUqyekLeDX2WHR3HtdIfUI-DJFJpxwfN6tL2nmkNpOuy8HkqfYm_nRWhhA-ULit4CQqekNdoBRbJMmqsxrnMN21rP87P7SxVAkws4cmEvO2FQgP_4PL-cAOMBPJrjSQPRpLgzW7cvDU220eT1v6z_Ql5NTRjT6yQq32ziTJaGkRb18go8ATA71JMyJPOfoexEQKajIHeemTZo8Ebt9TVt8hHrgHlZKl8dv2nPyd3eeduLOEHZG-92vgXAOjWxcvotX8B6wJGag priority: 102 providerName: ProQuest |
| Title | Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33435994 https://www.proquest.com/docview/2478833845 https://www.proquest.com/docview/2477496614 https://www.proquest.com/docview/2574356643 https://pubmed.ncbi.nlm.nih.gov/PMC7801864 https://doaj.org/article/9678dbea64ed41378bfd3ca4c8b2dedc |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZ2EYgXBONWGFVASDygQONLbD8g1E2dRqVOqGWob1bi2CNiSkrTDsav59hJo0ZME0-V4uOoOZecz_HxdxB6w1IijMUkpJzwkIrUhJLKLKQJ09jaAeeZOyg8OYtPz-l4zuY7aNPuqFFgdePSzvWTOl9evv_98_oTBPxHH_Ai_lBBzhLunLFbGFM5CPku2ofMxF2gTmi7qwBIxXPvORAeUoznm0M0N96jk6g8n_-_b-2ttNUtqdzKUScP0P0GXAbD2hseoh1THKA7dbvJ6wN0d9JspD9Cv0Yty3dQ2mA2nM7C4_JbiIPCrP3Hjz-Q0wJQe56WrtAwcAXycCG4MlXua1cDgI0e7uZVcJUv11WwKP0OspPbumG1yH-YwPNB5MVjdH4y-np8GjY9GEIdy3gVGiIH0gBmItxEmc1YJkxMNJZWG8msZUzDCoUQQxMbacz0gGhOWBSLyCZWEvIE7RVlYZ6hwHHvsVSSVDjSvSiTCR0QC29qmJIAzumhaKNwpRuCctcn41L5hYqIVW0kBUZS3kiK99C7ds6ipue4VfrI2bGVdNTa_kK5vFBNpCoJ6TtLTRJTk7nHFqnN4A9SLVKcgYF76LXzAuXIMwpXnXORrKtKfZ5N1TBmBFwswlEPvW2EbAnPoJPmsANowvFtdSQPO5IQ3bo7vHE2tQkOhV3PA0IEZT30qh12M13FXGHKtZfhVDr0dYsMg0gAPE9JDz2t_bfVDSEwJCXM5h3P7iivO1Lk3z0_OQfUI2L6_H8U9QLdw3XQhRE-RHur5dq8BJi3Svtol895H-0Ph-PZGH6PRmdfpn3_0aTv4_ovzCpQjA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELaqVjwuCMproYBBIA7I6saPJD4g1JZWLX0ItQX1ZhLHLhEoWZpuq_Kj-I3MOMnSCKm3XuNxlHjGM9_Y48-EvFa5SJ3ngslEJEymuWNa6oLJTFnu_ThJCjwovLsXb36Rn47U0Rz505-FwbLK3icGR13UFtfIlznyvEM-JdWHyS-Gt0bh7mp_hUZrFtvu4hxStub91kfQ7xvON9YP1zZZd6sAs7GOT5mDLF87QAEicVHhC1WkLhaWa2-dVt4rZQFzC-Fk5iPLlR0LmwgVxWnkM69xARRc_oIUkMrMk4XV9b3P-73vBywU2P0Q5jPJ-VF_TCeNlxuIrCmehsb0XeoxSwahMNwY8H9cuBQYh0Wbl6Lgxl1yp4OvdKW1t3tkzlWL5EZ7oeXFIrm5223V3yfn6zMecVp7erCyf8DW6q-M08pNw_LKb4iaFBRb5jWWMlIswYcH9Mw1ZaiOpQBMA6AuG3pWnkwbOqnDHjXKXXphMyl_OBoYJ8rqAflyLfp4SOarunKPCUV2P5VrkadI6xcVOpNj4SEWQJcMkNSIRP2AG9tRoONNHD9NSIXS2LRKMqAkE5RkkhF5N-szaQlArpReRT3OJJG8OzyoT45N5wuMBoBQ5C6LpSvwt9PcF_CB0qY5L0DBI_IKrcAgPUeF9T_H2bRpzNbBvlmJlQATi3g0Im87IV_DP9isO04BI4GMXgPJpYEk-A87bO6NzXT-qzH_ZtuIvJw1Y0-syatcPQ0yidSI766QUTATIGOQYkQetfY7GxshoElr6J0MLHsweMOWqvweGNATwFVpLJ9c_ekvyK3Nw90ds7O1t_2U3Obt1GMRXyLzpydT9wzg5Gn-vJvDlHy7brfxF5rchKE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+SARS-CoV-2+neutralizing+antibodies+using+a+vesicular+stomatitis+virus+possessing+SARS-CoV-2+spike+protein&rft.jtitle=Virology+journal&rft.au=Tani%2C+Hideki&rft.au=Kimura%2C+Miyuki&rft.au=Tan%2C+Long&rft.au=Yoshida%2C+Yoshihiro&rft.date=2021-01-12&rft.pub=BioMed+Central+Ltd&rft.issn=1743-422X&rft.eissn=1743-422X&rft.volume=18&rft.issue=1&rft_id=info:doi/10.1186%2Fs12985-021-01490-7&rft.externalDBID=ISR&rft.externalDocID=A653679121 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-422X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-422X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-422X&client=summon |